Compare Cassava Sciences Inc (FLNA) vs Google Inc (GOOG) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

GOOG trades at $357.33, up 1.9% today, with a bullish technical signal and strong support at $353. The company shows robust fundamentals with 2025 revenue of $402.84B, net income of $132.17B, and a net margin of 32.8%. Recent earnings beats and a consensus analyst price target of $457.50 highlight positive momentum, while news includes Warren Buffett's endorsement and strategic AI partnerships.

Outlook remains positive driven by earnings growth and AI expansion, but risks include regulatory fines and competitive pressures. Wall Street sentiment is strongly bullish with 87% buy ratings, suggesting upside potential, though investors should monitor execution and macroeconomic factors.